Treatment-related adverse events in patients with advanced breast cancer receiving adjuvant AKT inhibitors: a meta-analysis of randomized controlled trials.
Introduction: Incorporation of AKT inhibitors into adjuvant therapy for advanced or metastatic breast cancer has improved clinical outcomes. However, the safety of AKT inhibitors should be better evaluated, given the possibility of prolonging survival and impacting patient quality of life. Our aim w...
| Publicado en: | European Journal of Clinical Pharmacology Vol. 80; no. 9; pp. 1373 - 1386 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | research systematic review tables/charts Journal Article |
| Publicado: |
Springer Nature
Sep2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=178855720&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 178855720 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00316970 NP9 jtl: European Journal of Clinical Pharmacology issn: 00316970 maglogo: N pubinfo: dt: Sep2024 vid: 80 iid: 9 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 178855720 177941521 178855720 178855720 10.1007/s00228-024-03713-6 178855720 ppf: 1373 ppct: 13 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Treatment-related adverse events in patients with advanced breast cancer receiving adjuvant AKT inhibitors: a meta-analysis of randomized controlled trials. aug: au: de Moraes, Francisco Cezar Aquino Sano, Vitor Kendi Tsuchiya Pereira, Caroline R. M. de Laia, Estella Aparecida Stecca, Carlos Magalhães, Maria Cristina Figueroa Burbano, Rommel Mario Rodríguez affil: https://ror.org/03q9sr818 Department of Medicine, Federal University of Pará, 66073-005, BelemPará, Brazil sug: subj: Breast Neoplasms Therapy Protein Kinase Inhibitors Adverse Effects Antineoplastic Agents Adverse Effects Chemotherapy, Adjuvant Adverse Effects Human Meta Analysis Systematic Review Odds Ratio Descriptive Statistics Confidence Intervals Inferential Statistics Data Analysis Software Diarrhea Chemically Induced Hyperglycemia Chemically Induced Nausea Chemically Induced Exanthema Chemically Induced Stomatitis Chemically Induced Vomiting Chemically Induced Patient Safety Quality of Life Breast Neoplasms Prognosis ab: Introduction: Incorporation of AKT inhibitors into adjuvant therapy for advanced or metastatic breast cancer has improved clinical outcomes. However, the safety of AKT inhibitors should be better evaluated, given the possibility of prolonging survival and impacting patient quality of life. Our aim was to assess how the addition of AKT inhibitors to adjuvant therapy affects treatment-related adverse events. Methods: We evaluated binary outcomes with risk ratios (RRs), with 95% confidence intervals (CIs). We used DerSimonian and Laird random-effect models for all endpoints. Heterogeneity was assessed using I2 statistics. R, version 4.2.3, was used for statistical analyses. Results: A total of seven RCTs comprising 1619 patients with BC. The adverse effects that show significance statistical favoring the occurrence of adverse effects in AKT inhibitor were diarrhea (RR 3.05; 95% CI 2.48–3.75; p < 0.00001; I2 = 49%), hyperglycemia (RR 3.4; 95% CI 1.69–6.83; p = 0.00058; I2 = 75%), nausea (RR 1.69; 95% CI 1.34–2.13; p = 0.000008; I2 = 42%), rash (RR 2.79; 95% CI 1.49–5.23; p = 0.0013; I2 = 82%), stomatitis (RR 2.24; 95% CI 1.69–2.97; p < 0.00001; I2 = 16%) and vomiting (RR 2.99; 95% CI 1.85–4.86; p = 0.00009; I2 = 42%). There was no significant difference between the groups for alopecia (p = 0.80), fatigue (p = 0.087), and neuropathy (p = 0.363380). Conclusion: The addition of AKT inhibitors to adjuvant therapy was associated with an increase in treatment-related adverse events. These results provide safety information for further clinical trials evaluating AKT inhibitor therapy for patients with metastatic BC. Clinicians should closely monitor patients for treatment-related adverse events to avoid discontinuation of therapy and morbidity caused by these early-stage therapies. pubtype: Academic Journal doctype: meta analysis research systematic review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|